IL6 and COVID-19: In two reports with 15 and 20 patients each, COVID-19 patients treated with anti-IL-6 antibodies had C-reactive protein and lymphocyte levels returning to normal after treatment (Luo et al., 2020; Xu X. et al., 2020).